Abstract
Background A better understanding of the T cells in lung cancer and their distribution across tumor-adjacent lungs and the peripheral blood is needed to improve efficacy and minimize toxicity from immunotherapy to lung cancer patients.
Methods Here, we performed CDR3β TCR sequencing of 143 samples from 21 patients with early-stage NSCLC including peripheral blood mononuclear cells, tumor, tumor edges (<1cm from tumor), as well as adjacent lungs 1cm, 2cm, 5cm, and 10cm away from the tumor to gain insight into the spatial heterogeneity of T cells across the lungs in patients with NSCLC. PD-L1, CD4 and CD8 expression was assessed by immunohistochemical staining and genomic features were derived by targeted sequencing of 1,021 cancer related genes.
Results Our study reveals a decreasing gradient in TIL homology with the tumor-edge, adjacent lungs, and peripheral blood but no discernible distance-associated patterns of T cell trafficking within the adjacent lung itself. Furthermore, we show a decrease in pathogen-specific TCRs in regions with high T cell clonality and PD-L1 expression.
Conclusions The exclusion in T cells at play across the lungs of patients with NSCLC may be potentially the mechanism for lung cancer occurrence.
Competing Interest Statement
AR serves on the scientific advisory board and has received honoraria from Adaptive Biotechnologies. Jianjun Zhang reports that grants from Merck, Johnson and Johnson; adversary/consulting/hornoraria fees from Bristol Myers Squibb, AstraZeneca, Geneplus, Innovent, OrigMed, Roche outside the submitted work.
Funding Statement
This work was supported by the National Natural Science Foundation of China (81972195 to Dr. Fenglei Yu), Hunan Provincial Key Area R&D Program (2019SK2253 to Dr. Fenglei Yu), and the National Clinical Key Specialty Construction Project (to Dr. Fenglei Yu). This investigation was also supported by the Natural Science Foundation of Hunan Province (2022JJ30925 to Yang Gao) and the Project Program of National Clinical Research Center for Geriatric Disorders (Xiangya Hospital, Grant No. 2021LNJJ17 to Yang Gao)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of Second Xiangya Hospital Central South University (IRB: 2020084).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary materials. All data generated during this study are included in this published article and its supplementary information files. All data in this study are available from the corresponding author with a reasonable request.
List of Abbreviations
- ACT
- adoptive cell therapy
- CDR3
- complementarities determining region 3
- ICB
- immune checkpoint blockade
- ICP
- immune cells present
- IMGT
- ImMunoGeneTics
- MOI
- Morisita overlap index
- NSCLC
- non-small cell lung cancer
- TIL
- tumor infiltrating lymphocytes
- TMB
- Tumor mutational burden
